5 Gene Therapies That Could Shape Medicine

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T06:40:13.662Z • Permanent link

Sensational breakthroughs in gene therapy have been unfolding at an unprecedented pace, with several high-profile institutions and researchers making groundbreaking announcements in recent months. Dr. Francis Collins, Director of the National Institutes of Health (NIH), has been a key proponent of gene editing technologies, and his agency's investment in gene therapy research has yielded promising results. In April, the NIH announced a major grant to support the development of gene therapies for rare genetic diseases, highlighting the growing recognition of the potential for these technologies to transform medicine.

Touted as one of the most promising gene therapies is a treatment for Leber congenital amaurosis, a rare form of blindness caused by mutations in the RPE65 gene. The therapy, developed by gene therapy company, Spark Therapeutics, has shown remarkable efficacy in clinical trials, with some patients regaining significant vision. The company's lead candidate, voretigene neparvovec, has been submitted for FDA approval and is expected to become the first FDA-approved gene therapy for a rare eye disease. Other notable breakthroughs include the development of a gene therapy for sickle cell disease by Vertex Pharmaceuticals and a treatment for muscular dystrophy by Sarepta Therapeutics.

Groundbreaking research in gene editing has also been making headlines, with scientists at the Broad Institute of MIT and Harvard using CRISPR-Cas9 to edit human embryos for the first time. The research, published in the journal Nature, has sparked both excitement and controversy, with some experts arguing that it raises serious questions about the ethics of germline editing. However, the potential applications of CRISPR technology are vast, and researchers are already exploring its use in treating a range of diseases, from cancer to genetic disorders.

Researchers and clinicians are eagerly awaiting the arrival of these gene therapies on the market, which could revolutionize the treatment of rare and debilitating diseases. Companies like Spark Therapeutics and Vertex Pharmaceuticals are poised to reap significant rewards, with analysts predicting that their lead candidates could become billion-dollar blockbusters. The impact on the broader biotech industry is also significant, with many researchers and clinicians looking to gene therapy as a potential game-changer for their patients.

Spark Therapeutics, for example, has already seen its stock price soar in anticipation of FDA approval, with some analysts predicting that the company's lead candidate could generate over $1 billion in sales within the next few years. The company's CEO, Jeffrey Carroll, has been vocal about the potential of gene therapy to transform the treatment of rare diseases, and his company is widely seen as a leader in the field. Similarly, Vertex Pharmaceuticals has already seen its stock price rise in anticipation of FDA approval, with analysts predicting that the company's lead candidate could generate over $2 billion in sales within the next few years.

The development of gene therapies has been shaped by a complex interplay of technological, regulatory, and economic factors. The rise of gene editing technologies like CRISPR has created new opportunities for researchers to explore the potential of gene therapy, but it has also raised significant challenges and uncertainties. In the United States, the FDA has been slow to approve gene therapies, with some critics arguing that the agency's regulatory framework is too restrictive. However, the agency has been working to streamline its approval process, and several gene therapies have already been approved for use in the US.